Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFP464 in ER+ or Triple-negative Breast Cancer
NCT01015521Phase 2Withdrawn
- Sponsor
- Tigris Pharmaceuticals, Inc.
- Start
- Apr 2010
- Primary completion
- Dec 2012
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 2, open-label trial of AFP-464 in breast cancer (2 cohorts), sponsored by Tigris Pharmaceuticals, Inc. Primary endpoint: Clinical Benefit Response at 6 months. Planned start Apr 2010; status: withdrawn.
02
Drugs
AFP-464
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01015521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01015521.